CPT Code for Gonorrhea Chlamydia Screening
CPT Code for Gonorrhea Chlamydia Screening Screening for sexually transmitted infections such as gonorrhea and chlamydia is a vital component of preventative healthcare, especially given their prevalence among sexually active individuals. Proper documentation and coding are essential for reimbursement, data collection, and ensuring patients receive appropriate care. The Current Procedural Terminology (CPT) codes serve as standardized identifiers for these services, facilitating clear communication between healthcare providers and payers.
For gonorrhea and chlamydia screening, CPT codes are specific to the method of specimen collection and testing performed. Typically, these screenings involve nucleic acid amplification tests (NAATs), which are highly sensitive and specific for detecting these infections. NAATs can be performed on urine samples or swabs from the affected sites, such as the cervix, urethra, rectum, or oropharynx, depending on the patient’s sexual practices and risk factors.
The primary CPT code used for gonorrhea and chlamydia screening via NAAT is 87491. This code represents the detection of gonorrhea from a urine specimen or swab, using nucleic acid amplification techniques. For chlamydia, the CPT code 87491 is also frequently used when the test is performed on urine or swabs. When both infections are tested simultaneously from the same specimen, some payers may allow billing for both conditions using the same code, but it is essential to verify payer-specific guidelines.
In cases where separate testing methods are employed, or when additional procedures are involved, different CPT codes may be applicable. For example, if culture methods are used instead of NAAT, codes such as 87184 (for gonorrhea culture) or 87186 (for chlamydia culture) migh
t be applicable. However, NAATs are now the preferred testing method due to their superior accuracy and efficiency.
It is also important to note that CPT coding can vary depending on the setting of care—whether in a physician’s office, a laboratory, or a community health clinic—and whether the testing is performed as part of routine screening or diagnostic workup. Moreover, certain preventive services codes, such as those in the preventive medicine section, might be used in conjunction with these testing codes when screening is performed during an annual wellness visit.
Proper documentation is crucial. Healthcare providers should record the reason for testing, specimen type, and testing method used to support billing and avoid denials. Additionally, staying updated with the latest CPT coding guidelines and payer policies ensures accurate reimbursement and compliance.
In conclusion, CPT codes for gonorrhea and chlamydia screening primarily include 87491 for NAAT-based detection, applicable to various specimen types. Correct coding and thorough documentation help streamline billing processes, improve data accuracy, and promote effective public health responses to STIs.
